Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11590156 RNAi agents for hepatitis B virus infection

Overview Structured Data Issues Contributors Activity

Is a

Current Assignee

Arrowhead Pharmaceuticals, Inc.

Date Filed

August 11, 2020

Date of Patent

February 28, 2023

Patent Applicant

Arrowhead Pharmaceuticals, Inc.

Patent Application Number

16990916

Patent Citations

US Patent 10351852 RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)

US Patent 10590418 Methods and compositions for RNAi mediated inhibition of gene expression in mammals

US Patent 10780108 RNAi agents for Hepatitis B virus infection

US Patent 10806750 RNAi therapy for hepatitis B virus infection

US Patent 11020476 Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV)

US Patent 11174481 Targeting ligands

US Patent 11021692 Hepatitis B virus (HBV) vaccines and uses thereof

US Patent 10098959 Method for synthesis of reactive conjugate clusters

US Patent 10130651 RNAi Therapy for Hepatitis B Virus Infection

US Patent 10131907 Glycoconjugates of RNA interference agents

•••

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Patent Primary Examiner

CPC Code

Find more entities like US Patent 11590156 RNAi agents for hepatitis B virus infection

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.